Phase 1 Expansion Enrollment
Amp Volatility Score
Catalyst Info & Data Links
TITLE: Oraxol with pembrolizumab for Solid Tumors Phase 1 Expansion Enrollment
NCT03588039: Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors
WHAT IS THE NEXT CATALYST EVENT?
Phase 1 data
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
MECHANISM OF ACTION
P-glycoprotein (P-gp) is an active transport protein on the surface of the gastrointestinal (GI) tract. Many anticancer drugs are substrates of P-gp, and when orally administered, they will be pumped back into the GI tract, thereby limiting the drugs to intravenous administration. Encequidar, as a selective and potent P-gp inhibitor, has the potential to allow oral delivery of these chemotherapy agents. Current clinical trials are underway globally with encequidar combined with paclitaxel, docetaxel, irinotecan, eribulin, and topotecan.
Encequidar is a novel compound with inhibitory activity specific to P-gp. Encequidar’s distinguishing feature is its minimal oral absorption. This feature localizes P-gp inhibitory activity in the GI tract, improving the absorption of chemotherapy agents, but limiting the potential for unnecessary P-gp inhibition at other places in the body.
We believe the Orascovery approach will establish a new paradigm in the use of oral anticancer drugs.
Updated by MV
#ATNX #Oraxol #pembrolizumab #SolidTumors #cancer
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post